clinical dataGenmab shares rise following positive epcoritamab phase 3 dataGenmab and AbbVie reported positive phase 3 results for epcoritamab in combination with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), demonstrating a significant improvement … more ➔
Start-upsmartbax extends pre-series A to €6.3 m for new antibioticMunich-based smartbax has secured additional financing to advance its lead antibiotic programme, building on a €4.7m pre-Series A first close announced in October 2025. more ➔
clinical dataAbivax answers safety questions with new dataAbivax has reported additional Phase III maintenance data for obefazimod in ulcerative colitis, giving the French biotech more efficacy and safety evidence to support its planned US regulatory filing … more ➔
financeScancell plots reverse-merger path to NasdaqUK immunotherapy developer Scancell has confirmed talks to acquire Nasdaq-listed Neuphoria Therapeutics, in a move that could give the Oxford-based biotech a faster route to US public markets. more ➔
Start-upEMBL spin-off Epitome launches with €4MVienna-based Epitome Therapeutics has launched with €4 million in total financing to advance a new epigenome-editing platform designed to precisely control gene expression. more ➔
Watchlist8 European VC firms to watch in 2026European biotech enters 2026 in a strange, almost contradictory mood. The easy-money years are gone, the post-pandemic correction has done its damage, and investors are no longer rewarding science … more ➔
M&AIpsen buys Kartos in $1.75bn myelofibrosis pushParis-based Ipsen has agreed to acquire US biotech Kartos Therapeutics in a deal worth up to $1.75bn, adding a late-stage blood cancer programme to its growing oncology pipeline. more ➔
clinical dataProQR validates RNA editing platform and raises $59.2mProQR has reported the first clinical target-engagement data for its Axiomer RNA editing platform, while pricing a share offering and concurrent private placement that includes existing partner Eli … more ➔
licensingRecordati secures ex-U.S. rights to Ionis’ Alexander disease therapyItalian pharma Recordati has entered into a license agreement with Ionis Pharmaceuticals, Inc. for exclusive development and marketing rights to zilganersen, an investigational RNA-targeted medicine … more ➔
EmploymentADC Therapeutics cuts 17% of staff after safety setbackADC Therapeutics will cut about 17% of its global workforce as it tries to preserve cash and keep Zynlonta’s regulatory strategy on track after a difficult Phase III readout. more ➔
